Dermatology & Plastic Surgery Institute Outcomes
Surgical Quality Improvement
Brain Tumor Surgery Outcomes
Brain Tumor Surgery ACS NSQIP Outcomes
January 1, 2023 – December 31, 2023
The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) objectively measures and reports risk-adjusted surgical outcomes based on a defined sampling and abstraction methodology. These outcomes data reflect Cleveland Clinic’s overall brain tumor surgery ACS NSQIP performance benchmarked against 199 participating sites.
| Brain Tumor (199 Sites) | N | Observed | Expected |
|---|---|---|---|
| 30 Day Mortality | 310 | 2.58% | 2.34% |
| 30 Day Morbidity | 310 | 12.58% | 9.46% |
| Cardiac | 310 | 0.00% | 0.43% |
| Pneumonia | 310 | 2.26% | 2.15% |
| Unplanned Intubation | 309 | 2.59% | 1.70% |
| Ventilator > 48 Hours | 308 | 3.57% | 1.64% |
| Tumor Deep Vein Thrombosis (DVT) / Pulmonary Embolus | 310 | 6.77% | 2.69% |
| Urinary Tract Infection (UTI) | 310 | 1.29% | 1.55% |
| Surgical Site Infection (SSI) | 310 | 3.23% | 1.87% |
| Sepsis | 310 | 2.58% | 1.43% |
| Unplanned Reoperation | 310 | 4.19% | 4.53% |
| Length of Stay | 261 | 16.48% | 21.26% |
| Unplanned Readmission | 310 | 12.58% | 9.84% |
American College of Surgeons National Surgical Quality Improvement Program, 2024.
ACS NSQIP® Semiannual Report July 8, 2024, Chicago: American College of Surgeons.
